Andrea Mari Selected Research

Incretins

1/2022	Loss of the Incretin Effect in Type 2 Diabetes: A Systematic Review and Meta-analysis.
1/2021	The Impact of Low-dose Gliclazide on the Incretin Effect and Indices of Beta-cell Function.
1/2021	Different mechanisms of GIP and GLP-1 action explain their different therapeutic efficacy in type 2 diabetes.
1/2020	Persistent whole day meal effects of three dipeptidyl peptidase-4 inhibitors on glycaemia and hormonal responses in metformin-treated type 2 diabetes.
1/2019	Bile Modulates Secretion of Incretins and Insulin: A Study of Human Extrahepatic Cholestasis.
1/2018	Effects of acute NEFA manipulation on incretin-induced insulin secretion in participants with and without type 2 diabetes.
1/2018	Effect of single-dose DPP-4 inhibitor sitagliptin on β-cell function and incretin hormone secretion after meal ingestion in healthy volunteers and drug-naïve, well-controlled type 2 diabetes subjects.
1/2017	Differences in β-cell function and insulin secretion in Black vs. White obese adolescents: do incretin hormones play a role?
11/2014	β-cell function, incretin effect, and incretin hormones in obese youth along the span of glucose tolerance from normal to prediabetes to type 2 diabetes.
10/2014	β-Cell function in type 2 diabetes.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Andrea Mari Research Topics

Disease

112	Insulin Resistance 04/2024 - 12/2002
84	Type 2 Diabetes Mellitus (MODY) 04/2024 - 09/2002
46	Neoplasms (Cancer) 02/2024 - 01/2015
35	Urinary Bladder Neoplasms (Bladder Cancer) 04/2024 - 12/2017
24	Carcinoma (Carcinomatosis) 03/2024 - 03/2017
22	Glucose Intolerance 05/2024 - 01/2005
16	Hyperglycemia 01/2022 - 02/2002
15	Non-Muscle Invasive Bladder Neoplasms 01/2024 - 01/2018
14	Renal Cell Carcinoma (Grawitz Tumor) 04/2024 - 01/2018
13	Hyperinsulinism (Hyperinsulinemia) 05/2024 - 06/2006
12	Prediabetic State (Prediabetes) 05/2024 - 11/2014
11	Obesity 04/2024 - 12/2004
11	Weight Loss (Weight Reduction) 01/2022 - 12/2004
10	Prostatic Neoplasms (Prostate Cancer) 05/2024 - 01/2018
10	Cardiovascular Diseases (Cardiovascular Disease) 01/2024 - 10/2010
8	Acute Kidney Injury (Acute Renal Failure) 06/2023 - 01/2020
7	Neoplasm Metastasis (Metastasis) 05/2023 - 01/2018
7	Disease Progression 04/2023 - 01/2019
7	Margins of Excision 09/2021 - 12/2017
6	Kidney Neoplasms (Kidney Cancer) 11/2023 - 01/2019
6	Chronic Renal Insufficiency 10/2023 - 01/2017
5	Intraoperative Complications 09/2023 - 02/2019
5	Body Weight (Weight, Body) 01/2023 - 03/2007
4	Inflammation (Inflammations) 03/2024 - 10/2019
4	Carcinoma in Situ 01/2022 - 01/2019
4	Prostatic Hyperplasia (Benign Prostatic Hyperplasia) 01/2022 - 01/2020
4	Penile Induration (Peyronie's Disease) 04/2021 - 10/2018
3	Thrombosis (Thrombus) 04/2024 - 08/2019
3	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 01/2023 - 01/2021
3	Dyslipidemias (Dyslipidemia) 01/2022 - 10/2010
3	Ischemia 11/2021 - 05/2005
3	Non-alcoholic Fatty Liver Disease 01/2021 - 04/2012
3	Overweight 01/2020 - 08/2011
3	Glycosuria 04/2016 - 02/2014
2	Hypertriglyceridemia 04/2024 - 01/2022
2	Cystitis 03/2024 - 10/2019
2	Urinary Incontinence 10/2023 - 09/2017
2	Cystic Fibrosis (Mucoviscidosis) 03/2023 - 01/2019

Drug/Important Bio-Agent (IBA)

133	Glucose (Dextrose)FDA LinkGeneric 05/2024 - 09/2002
74	Insulin (Novolin)FDA Link 04/2024 - 02/2002
31	C-PeptideIBA 01/2023 - 12/2002
17	IncretinsIBA 01/2022 - 12/2002
13	Glucagon-Like Peptide 1 (GLP 1)IBA 04/2024 - 10/2003
12	Biomarkers (Surrogate Marker)IBA 03/2023 - 06/2011
11	Glucagon (Glukagon)FDA Link 04/2024 - 06/2011
10	LipidsIBA 04/2024 - 11/2007
9	Nonesterified Fatty Acids (NEFA)IBA 04/2024 - 06/2006
8	Hormones (Hormone)IBA 01/2021 - 12/2006
7	Metformin (Glucophage)FDA LinkGeneric 01/2022 - 04/2016
6	CarbohydratesIBA 04/2021 - 02/2009
6	Triglycerides (Triacylglycerol)IBA 12/2018 - 12/2011
5	CreatinineIBA 05/2023 - 01/2015
5	Cisplatin (Platino)FDA LinkGeneric 12/2022 - 01/2018
4	Fatty Acids (Saturated Fatty Acids)IBA 04/2024 - 01/2009
4	EnzymesIBA 02/2023 - 06/2011
4	Blood Glucose (Blood Sugar)IBA 01/2023 - 04/2012
4	lixisenatideIBA 06/2022 - 01/2020
4	Peptides (Polypeptides)IBA 01/2022 - 06/2014
4	Hemoglobins (Hemoglobin)IBA 01/2020 - 04/2007
3	Glucagon-Like Peptide-1 ReceptorIBA 01/2022 - 10/2014
3	Arginine (L-Arginine)FDA Link 01/2021 - 04/2013
3	Glycated Hemoglobin (Glycosylated Hemoglobin)IBA 01/2021 - 01/2008
3	Sitagliptin Phosphate (Januvia)FDA Link 01/2018 - 08/2012
3	Sodium-Glucose Transporter 2 InhibitorsIBA 04/2016 - 05/2014
3	Prednisolone (Predate)FDA LinkGeneric 03/2014 - 04/2010
3	GlucocorticoidsIBA 03/2014 - 04/2010
2	pembrolizumabIBA 04/2024 - 11/2023
2	Hyaluronic Acid (Hyaluronan)IBA 03/2024 - 04/2021
2	Sucrose (Saccharose)IBA 02/2024 - 04/2017
2	2-methylcyclopentadienyl manganese tricarbonyl (MMT)IBA 02/2024 - 01/2020
2	Indicators and Reagents (Reagents)IBA 01/2024 - 11/2020
2	LeptinIBA 08/2023 - 04/2014
2	AdipokinesIBA 08/2023 - 07/2006
2	GlucokinaseIBA 02/2023 - 04/2012
2	Dietary Advanced Glycation End ProductsIBA 01/2023 - 01/2022
2	AutoantibodiesIBA 01/2023 - 01/2021
2	Advanced Glycation End ProductsIBA 01/2023 - 01/2022

Therapy/Procedure

39	Nephrectomy 04/2024 - 01/2015
28	Therapeutics 04/2024 - 03/2014
24	Cystectomy 04/2024 - 02/2018
19	Nephroureterectomy 03/2024 - 09/2017
11	Prostatectomy (Retropubic Prostatectomy) 05/2024 - 09/2017
11	Lymph Node Excision (Lymph Node Dissection) 03/2024 - 03/2017
11	Bariatric Surgery 01/2021 - 12/2004
10	Immunotherapy 11/2023 - 10/2020
9	Drug Therapy (Chemotherapy) 01/2024 - 01/2018
8	Glycemic Control 01/2023 - 09/2005
7	Neoadjuvant Therapy 01/2024 - 08/2020
7	Transurethral Resection of Bladder 01/2023 - 01/2019
5	Warm Ischemia 10/2022 - 01/2020
4	Adjuvant Chemotherapy 01/2023 - 01/2022
4	Length of Stay 01/2022 - 02/2019
3	Operative Time 04/2022 - 05/2015
3	Minimally Invasive Surgical Procedures 01/2022 - 08/2019
3	Gastric Bypass (Roux-en-Y Gastric Bypass) 01/2019 - 11/2013
2	Intravesical Administration 01/2024 - 12/2020
2	Operative Surgical Procedures 10/2023 - 08/2020
2	Carbohydrate-Restricted Diet (Low Carbohydrate Diet) 02/2023 - 04/2021
2	Blood Transfusion (Blood Transfusions) 02/2023 - 12/2022
2	Enhanced Recovery After Surgery 11/2022 - 11/2020